Bronchiectasis insanity: Doing the same thing over and over again and expecting different results?

Mark Metersky (Lead / Corresponding author), James Chalmers

Research output: Contribution to journalReview articlepeer-review

11 Citations (Scopus)
134 Downloads (Pure)


Bronchiectasis is an increasingly common disease with a significant impact on quality of life and morbidity of affected patients. It is also a very heterogeneous disease with numerous different underlying etiologies and presentations. Most treatments for bronchiectasis are based on low-quality evidence; consequently, no treatments have been approved by the US Food and Drug Administration or the European Medicines Agency for the treatment of bronchiectasis. The last several years have seen numerous clinical trials in which the investigational agent, thought to hold great promise, did not demonstrate a clinically or statistically significant benefit. This commentary will review the likely reasons for these disappointing results and a potential approach that may have a greater likelihood of defining evidence-based treatment for bronchiectasis.

Original languageEnglish
Article number293
Pages (from-to)1-7
Number of pages7
Publication statusPublished - 15 Mar 2019


  • Bronchiectasis
  • Clinical trial
  • Treatment

ASJC Scopus subject areas

  • General Biochemistry,Genetics and Molecular Biology
  • General Immunology and Microbiology
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Bronchiectasis insanity: Doing the same thing over and over again and expecting different results?'. Together they form a unique fingerprint.

Cite this